Cinnarizine
- done All payments are SSL encrypted
- done Full Refund if you haven't received your order
- done International shipping to the USA, UK and Europe
Clinical Pharmacology
- The drug blocks the passage of calcium ions through the cell membrane. This helps to reduce their presence in the depot.
- The tool reduces tinnitus, reduces headache. This happens because the property of the medicine to improve the condition of the blood vessels helps normalize the cerebral circulation.
- Arteriole smooth muscle tone decreases. Peripheral and coronary blood circulation is improved, tissues are supplied with blood more fully. Possible post-ischemic hyperemia.
- Biogenic vasoconstrictor substances after taking the drug do not have an adequate response from the body, because cinnarizine is able to suppress them. The ability of cinnarizine to exhibit antihistamine activity in moderate amounts also works to improve blood circulation.
- The ingredients of the drug have an effect on blood cells, reduce its viscosity. Erythrocytes under the influence of the means improve the condition of the membranes, increasing their elasticity. The drug helps the cells to survive in conditions of lack of oxygen.
Indications
The tool is prescribed for such diseases:
- peripheral circulation is deteriorating and it manifests itself as:
- Raynaud's disease
- thromboangiitis obliterans,
- intermittent claudication
- diabetic angiopathy,
- thrombophlebitis,
- pregangrenous conditions
- trophic disorders, including ulcers;
- ischemic stroke,
- senile dementia,
- encephalopathy,
- prevention of migraine attacks,
- states after strokes
- prevention of kinetoz,
- head injuries,
- vestibular disorders.
Composition
Active ingredient: 25 mg cinnarizine
Additional ingredients:
- povidone,
- lactose,
- magnesium stearate,
- wheat starch
- silica.
Cinnarizine is marketed under different brands and generic names, and comes in different dosage forms:
Brand name | Manufacturer | Country | Dosage form |
---|---|---|---|
Cinnarizine | Anzhero-Sudzhensky HFZ | Russia | pills |
Cinnarizine | PFK Obnovlenie | Russia | pills |
Cinnarizine | Pharma AD | Bulgaria | pills |
Stugeron | Gedeon Richter | Hungary | pills |
Cinnarizine | Sopharma | Bulgaria | pills |
No customer reviews for the moment.
Dosage and Administration
Inside, after eating.
In case of insufficiency of cerebral circulation - 25 mg 3 times / day.
In case of violation of the peripheral circulation - 50-75 mg 3 times / day.
When vestibular disorders - 25 mg 3 times / day.
The maximum recommended dose should not exceed 225 mg (9 pills) per day. The course of treatment from several weeks to several months.
In case of kinetosis (road sickness): for adults - 25 mg per half hour before the road (if necessary, 25 mg reapptake after 6 hours), for children from 5 years old - 1/2 dose recommended for adults.
With high sensitivity to the drug, treatment starts from 1/2. dose, increasing it gradually.
Adverse reactions
Nervous system disorders: drowsiness, fatigue, headache, extrapyramidal disorders (tremor of the limbs and increased muscle tone, hypokinesia), depression.
On the part of the digestive system: dry mouth, pain in the epigastric region, dyspepsia, cholestatic jaundice.
On the part of the skin: sweating, the development of lupus-like syndrome, lichen planus (extremely rare), skin rash.
Other: allergic reactions, weight gain.
Contraindications
- hypersensitivity;
- pregnancy;
- lactation period;
- children's age up to 5 years.
With caution in Parkinson's disease.
Drug interactions
Strengthens the inhibitory effect on the central nervous system of alcohol, sedatives, tricyclic antidepressants. Due to the presence of an antihistamine effect, cinnarizine can affect the result of the athletes' anti-doping control (false positive result), and can also neutralize positive reactions during skin diagnostic tests (4 days before the study, treatment should be canceled).
Special instructions
Patients with Parkinson’s disease are prescribed only when the benefits of treatment with cinnarizine exceed the possible worsening of the course of the underlying disease.
At the beginning of treatment can cause drowsiness, so taking alcohol and the simultaneous use of CNS depressants requires caution.
In connection with the antihistamine effect, cinnarizine should be discontinued 4 days before the allergic skin test. Cinnarizine can affect the result in athletes' anti-doping control (false positive).
In case of lactose intolerance, please note that 1 tablet contains 175 mg of lactose.
Influence on ability to steer the car and other working mechanisms
Drowsiness may develop, especially at the beginning of treatment, so care should be taken when driving vehicles and engaging in other potentially hazardous activities that require increased concentration and psychomotor speed. With prolonged use, it is recommended to conduct a laboratory test of the liver, kidney, and peripheral blood.
Overdosage
Symptoms: increased severity of side effects, decreased blood pressure, vomiting, coma.
Treatment: there is no specific antidote, gastric lavage, taking activated charcoal, symptomatic therapy.
- Cinnarizine-induced parkinsonism: Ten years later
- Comparison of the effects of vinpocetine, vincamine, phenytoin, and cinnarizine in a rat model of cerebral ischemia
- The effects of single and repeated doses of oral scopolamine, cinnarizine, and placebo upon psychological performance and physiological functioning
- Enhancement of bioavailability of cinnarizine from its β-cyclodextrin complex on oral administration with DL-phenylalanine as a competing agent
- Enhancement of bioavailability of cinnarizine from its β-cyclodextrin complex on oral administration with dl-phenylalanine as a competing agent
- Enhancement of the oral bioavailability of cinnarizine in oleic acid in beagle dogs
- Movement disorders and depression due to flunarizine and cinnarizine
- A long-term follow-up study of cinnarizine- and flunarizine-induced parkinsonism
- Cinnarizine-induced parkinsonism: Ten years later
- Potentiometric membrane sensors for the selective determination of cinnarizine in pharmaceutical preparations
- Synthesis and pharmacological study of new calcium antagonists, analogues of cinnarizine and flunarizine
- Formulation, stability and degradation kinetics of intravenous cinnarizine lipid emulsion
- Pharmacokinetics, tissue distribution and safety of cinnarizine delivered in lipid emulsion
- A microcalorimetric investigation of the binding of cinnarizine to cyclodextrins
- Flow-injection determination of cinnarizine using surfactant-enhanced permanganate chemiluminesence
- Method development and validation for the simultaneous determination of cinnarizine and co-formulated drugs in pharmaceutical preparations by capillary electrophoresis
- Determination of cinnarizine in plasma by high-performance liquid chromatography
- Determination of cinnarizine in plasma by high-performance liquid chromatography
- Sensitive gas chromatographic method for the determination of cinnarizine and flunarizine in biological samples
- LC and TLC determination of cinnarizine in pharmaceutical preparations and serum
- Simultaneous determination of domperidone maleate and cinnarizine in a binary mixture using derivative ratio spectrophotometry and classical least squares calibration
- Simultaneous determination of cinnarizine and domepiridone maleate from tablet dosage form by reverse phase ion pair high performance liquid chromatography
- Promethazine, scopolamine and cinnarizine: comparative time course of psychological performance effects